About the Company

Plair was born from a simple but powerful idea: what if we could detect microbial threats in the air before they became a problem? Founded in Geneva as a spin-off from academic research, Plair developed a unique in-house technology. The founders turned it into the first integrated solution (Rapid-C+) to monitor air in sterile manufacturing environments.

What started as an innovation in environmental monitoring has evolved into a breakthrough for sterile manufacturing. Today, Plair empowers high-value, regulated industries like pharma to prevent contamination, protect production, and meet the highest quality standards — resulting in significant waste reduction, lower contamination risks and more sustainable processes.

Company at a Glance

• Validated & market-ready: After successfully piloting its technology with blue-chip companies, Plair is now ready for industrial rollout.
• Patented & first-mover: Plair holds over six international patents protecting its unique, in-house-developed technology for real-time microbial detection.
• Scalable & in demand: With first systems delivered over a broad spectrum of application and over CHF 6M revenue generated so far, Plair is gaining traction and already securing contracts with leading pharmaceutical companies. 
• Regulatory-aligned & future-ready: Plair’s technology aligns with FDA, EMA, and GMP guidelines, ensuring long-term fit in regulated markets. Plair’s products are not subject to an approval by an agency like FDA or EMA.

Benefits for Co-Owners and Investors

As a co-owner of Plair, you benefit from the following advantages:

• Unique-mover position in a booming market: Plair is the only supplier on the market to provide an instrument integrating full microbial monitoring solution, real-time and traditional agar sampling  - entering a $10B+ market with strong demand.
• Scalable business with recurring revenue: With first systems sold and more in the pipeline, Plair combines hardware margins with long-term recurring laboratory and annual service revenues.
• Strong exit potential: Comparable companies have exited at 5-6x revenue multiples. Plair’s exit range is projected between $100M and $200M.
• Encouraging cleaner, safer production: Plair reduces production waste and enhances safety in sterile environments - contributing to UN SDGs 3, 9, 11, and 12.

We are looking for investors who believe in science-driven innovation and scalable deep tech and who want to join us in becoming the world leader in real-time microbial air monitoring.

Milestones

Our Vision - Why Invest in Plair

Plair’s vision is clear: to become the global leader in real-time microbial monitoring. With its unique, patented technology, the company is redefining how regulated industries such as pharmaceuticals prevent contaminations during production, every step of the way, considerably raising safety and lowering batch waste and use of consumables  - making production faster, safer, and smarter.

With the funds from this crowdinvesting campaign, Plair will scale up its sales, strengthen its marketing impact, and accelerate international expansion, particularly into the high-margin U.S. market. A portion of the funds will also support onboarding of new pharma customers and further automation of regulatory validation workflows.

As an investor, you’re not only participating in a fast-growing industrial tech company, you’re enabling the shift from outdated microbial monitoring to a real-time standard that increases safety, reduces loss, and ensures sustainable production.

Now is the time to invest in a company that is first to market, backed by global pilots, and positioned for scale in a $10B+ market.

FAQ

Why did you choose crowdinvesting for financing?

We want to give individual investors the opportunity to join Plair’s growth journey. Crowdinvesting allows us to build a strong community of supporters while keeping our strategy and technology independent and founder-led.

How did you come up with the company valuation?

Our valuation is based on current and projected revenues, our patented technology, existing partnerships, and comparable exit multiples in the sector. Full financial details are available in our pitch deck.

Do I get voting rights?

Plair will offer shares during the pre-funding phase, which do include voting rights. In the funding phase, investors receive participation certificates, which do not carry voting rights. However, in both cases, you become a co-owner of the company and benefit from any potential increase in its value.

Will I receive dividends?

Not in the short term. Plair is focused on growth and reinvestment. Dividends are not planned, but you will participate in any future exit or acquisition upside.

Is an exit planned?

Yes. Plair is built with a clear exit strategy. Comparable companies have exited at 5-6x revenue multiples. We project an exit value between $100M and $200M depending on market traction and scale.

Together with you, we want to set a new standard in microbial monitoring - because sterile production deserves real-time protection, and now is the time to scale a breakthrough technology into a global market.